CEL-SCI Corporation (CVM)
NYSEAMERICAN: CVM · Real-Time Price · USD
10.25
+0.42 (4.27%)
Sep 12, 2025, 4:00 PM EDT - Market closed
CEL-SCI Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
44
Market Cap
81.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | - | - | - |
| Sep 30, 2023 | - | - | - |
| Sep 30, 2022 | - | - | - |
| Sep 30, 2021 | - | - | - |
| Sep 30, 2020 | 558.66K | 95.91K | 20.73% |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CVM News
- 16 days ago - CEL-SCI Announces Closing of $10 Million Public Offering - Business Wire
- 18 days ago - CEL-SCI Announces Pricing of $10 Million Public Offering - Business Wire
- 18 days ago - CEL-SCI Announces Proposed Public Offering - Business Wire
- 4 weeks ago - CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results - Business Wire
- 4 weeks ago - CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline - Business Wire
- 2 months ago - CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules - Business Wire
- 2 months ago - CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules - Business Wire
- 2 months ago - CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer - Business Wire